Category: News Items

ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer ANN ARBOR, MI – February 9, 2022 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Sushanta Mallick, PhD, MBA, to the newly created position of Chief Development Officer. As CDO, Dr.…

ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle glaucoma (OAG) and geographic atrophy (GA) associated with age-related macular degeneration (AMD) Phase 1b studies in patients with OAG and GA will evaluate safety, pharmacokinetics and preliminary…

ONL Therapeutics Names Connie Chang as Chief Operating Officer Company expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related macular degeneration ANN ARBOR, MI – January 19, 2021 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients…

ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration over the next 24 months ANN ARBOR, MI – December 22, 2020 ONL Therapeutics, Inc., a biopharmaceutical company…

ONL Therapeutics featured on the OIS Retina Podcast ANN ARBOR, MI – June 30, 2020 This week’s special guest on the OIS Retina Podcast is David Esposito, CEO of ONL Therapeutics. A West Point graduate who served as a platoon leader in the first Gulf War, Esposito began his career in ophthalmology as a pharmaceutical sales rep for…

ONL Therapeutics Announces First Patient Treated in Phase I Study With ONL1204 ONL Therapeutics transformed into a clinical stage biopharmaceutical company with first-in-human study ANN ARBOR, MI – October 23, 2019 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first patient…

ONL Therapeutics Announces First-in-human Clinical Study With ONL1204 Lead candidate ONL1204 advances into Phase I clinical study in retinal detachment in Australia ANN ARBOR, MI – October 8, 2019 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the initiation of the company’s First-in-Human…

ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 Into First-in-Human Clinical Study Lead candidate ONL1204 will advance to Phase I clinical study in retinal detachment in late 2019 ANN ARBOR, MI – August 22, 2019 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with…

ONL Therapeutics Names Industry Veteran as CEO as Company Prepares for First In Human Clinical Trials David A. Esposito Appointed President and Chief Executive Officer as Company Accelerates Preparation of ONL1204 for Retinal Detachment Clinical Trial ANN ARBOR, MI – June 18, 2019 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving vision…